SCHEMBL4761976

SCHEMBL4761976

CCOCc1cc(-c2ccc3c(c2)c2cc(-c4ccc(F)cc4)c(=O)n(C)c2n3C)n[nH]1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ MAPK14 Q16539 2/20 0.33
▸ MAPT P10636 2/20 0.32
▸ METAP2 P50579 1/20 0.32
▸ RET P07949 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ PRMT5 O14744 1/20 0.31
▸ WDR77 Q9BQA1 1/20 0.31
▸ PLK1 P53350 3/20 0.31
▸ NR1H4 Q96RI1 1/20 0.30
▸ HTR1A P08908 1/20 0.30
▸ HTR1B P28222 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339069 0.84 GABRA1 (0.36) KDM4EALDH1A1GABRA1GABRG2GABRB3
SCHEMBL1339171 0.84 KDM4E (0.35) KDM4EALDH1A1GABRA1GABRG2GABRB3
SCHEMBL1339370 0.82 L3MBTL1 (0.40) KDM4EALDH1A1GABRA1GABRG2GABRB3
SCHEMBL1336985 0.80 MAPK14 (0.37) KDM4EGABRA1GABRG2GABRB3GABRA5
SCHEMBL1339384 0.79 GABRA1 (0.36) KDM4EALDH1A1GABRA1GABRG2GABRB3
SCHEMBL1340490 0.76 DRD2 (0.36) KDM4EGABRA1GABRG2GABRB3GABRA5
SCHEMBL3126783 0.75 GABRA1 (0.36) KDM4EGABRA1GABRG2GABRB3GABRA5
SCHEMBL1338502 0.75 GABRA1 (0.35) GABRA1GABRG2GABRB3GABRA5MAPT
Hydrochloric Acid SCHEMBL1339338 0.75 GABRA1 (0.35) GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338537 0.74 L3MBTL1 (0.44) GABRA1GABRG2GABRB3GABRA5MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 KDM4E 1908/4885ALDH1A1 283/4885GABRA1 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback